文献速递胸部肿瘤

贝伐珠单抗联合辅助化疗治疗已切除非小细胞肺癌的III期试验

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-11-09

E1505研究是一项开放标签、多中心、随机III期试验,纳入1501例完全切除的IB-IIIA期NSCLC患者,比较辅助化疗联合或不联合贝伐珠单抗的疗效。

要点

  • 辅助化疗联合贝伐珠单抗未改善已切除早期NSCLC的总生存。
  • 贝伐珠单抗组3-5级毒性发生率更高(83% vs 67%),高血压和中性粒细胞减少更常见。
  • 贝伐珠单抗不应考虑用于已切除早期NSCLC的辅助治疗。

核心结论

  • 在已切除早期NSCLC患者中,辅助化疗联合贝伐珠单抗未改善总生存。
  • 贝伐珠单抗在该 setting 中无作用,不应作为辅助治疗。

研究设计与样本

  • 开放标签、多中心、随机III期试验,纳入1501例完全切除的IB期(≥4 cm)至IIIA期NSCLC成人患者。
  • 患者随机1:1接受辅助化疗(A组)或化疗联合贝伐珠单抗(B组),化疗为4周期含顺铂方案。
  • 贝伐珠单抗15 mg/kg每21天一次,从化疗第1周期开始,持续1年。
  • 主要终点为总生存,按意向治疗分析。

主要发现

  • B组3-5级总体毒性发生率为83%(610/735),A组为67%(496/738)。
  • B组高血压发生率30%(219/735),A组8%(60/738);中性粒细胞减少B组37%(275/735),A组33%(241/738)。
  • 治疗期间死亡A组15例,B组19例;其中至少可能与治疗相关的死亡A组3例,B组10例。

关键数值与推荐

  • 分期分布:IB期383例(26%),II期636例(44%),IIIA期439例(30%),43例分期缺失。
  • 鳞癌422例(28%)。
  • 化疗方案:长春瑞滨377例(25%),多西他赛343例(23%),吉西他滨283例(19%),培美曲塞497例(33%)。

临床怎么用

  • 对于已切除的早期NSCLC,辅助化疗不应联合贝伐珠单抗。
  • 贝伐珠单抗在该辅助治疗场景中无适应症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. METHODS: We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805. FINDINGS: Between June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment. INTERPRETATION: Addition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC. FUNDING: National Cancer Institute of the National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 29129443. doi:10.1016/S1470-2045(17)30691-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。